Linked Life Data

7765070

Source:http://linkedlifedata.com/resource/pubmed/id/7765070

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1994-9-13
pubmed:abstractText
Selective delivery of lethal levels of drugs to tumors, without concomitant damage to normal tissues, is a major challenge in cancer chemotherapy. Prodrugs used in conjunction with enzyme-monoclonal antibody conjugates that can target tumors and convert prodrugs to their active drug forms in situ, offer exceptional promise in achieving this objective. Synthesis of prodrugs, acquisition of appropriate enzymes and monoclonal antibodies, and manufacture of conjugates afford considerable flexibility in experimental design.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
B
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0167-7799
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
234-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
pubmed:affiliation
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review, Research Support, Non-U.S. Gov't